Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 34.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 446,364 shares of the biopharmaceutical company’s stock after buying an additional 115,361 shares during the period. Natixis Advisors LLC’s holdings in Bristol-Myers Squibb were worth $23,095,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Bessemer Group Inc. increased its position in Bristol-Myers Squibb by 16.3% in the 1st quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company’s stock valued at $8,625,000 after acquiring an additional 22,286 shares during the period. Lake Street Advisors Group LLC lifted its holdings in Bristol-Myers Squibb by 54.7% in the 1st quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company’s stock valued at $734,000 after acquiring an additional 4,784 shares during the last quarter. Pitcairn Co. lifted its stake in Bristol-Myers Squibb by 152.3% during the first quarter. Pitcairn Co. now owns 48,250 shares of the biopharmaceutical company’s stock valued at $2,617,000 after purchasing an additional 29,128 shares during the last quarter. Ossiam boosted its stake in shares of Bristol-Myers Squibb by 31.7% during the 1st quarter. Ossiam now owns 88,183 shares of the biopharmaceutical company’s stock worth $4,782,000 after acquiring an additional 21,234 shares in the last quarter. Finally, Leelyn Smith LLC boosted its position in shares of Bristol-Myers Squibb by 4.6% in the 1st quarter. Leelyn Smith LLC now owns 38,525 shares of the biopharmaceutical company’s stock valued at $2,089,000 after purchasing an additional 1,681 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of a number of research analyst reports. TD Cowen lifted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Wolfe Research started coverage on shares of Bristol-Myers Squibb in a report on Friday. They set a “peer perform” rating on the stock. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Citigroup lifted their price objective on Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Stock Performance

BMY opened at $56.81 on Tuesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The business has a fifty day simple moving average of $52.90 and a 200 day simple moving average of $47.37. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08. The company has a market capitalization of $115.22 billion, a PE ratio of -15.82, a price-to-earnings-growth ratio of 15.23 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the previous year, the firm earned $2.00 EPS. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. Research analysts expect that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.22%. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.